An obstructing rectal gastrointestinal stromal tumour diagnosed using endoscopic ultrasonography

Paul J Belletrutti MD FRCPC, Lorne Price MD FRCPC

CASE PRESENTATION
A 53-year-old Caucasian man presented with a several-month history of progressive obstipation. At the time of presentation to hospital, he had been unable to have a bowel movement for 10 days. He was otherwise healthy with no other medical diagnoses. He was not taking any medications but was an active cigarette smoker.

On digital rectal examination, a large, smooth, rounded mass was immediately palpable in the rectal vault. At proctoscopy, a large mass with edematous overlying mucosa occupied the rectum. Mucosal biopsies showed reactive inflammatory changes but no evidence of neoplasia. A computed tomography scan delineated a solid 9 cm × 7 cm mass in the pelvis suspected to be of prostatic or urothelial origin (Figure 1). However, rectal endoscopic ultrasonography (EUS) depicted a hypoechoic mass clearly arising from muscularis propria layer of the rectal wall (Figure 2, red arrow) with a clear plane apparent between the mass and prostate gland (Figure 2, green arrow).

EUS-guided fine-needle aspiration cytology revealed a spindle cell neoplasm that stained positively for CD-117 (c-KIT) and CD-34, confirming the diagnosis of a gastrointestinal (GI) stromal tumour (GIST). The patient received neoadjuvant imatinib therapy with a resultant 50% reduction in tumour volume. The hope was to perform a sphincter preserving resection; however, a complete mesorectal and perineal resection was required due to tumour adherence. On final pathology, a 4.6 cm × 5 cm GIST was confirmed (Figure 3). The mitotic count was 1/50 high-powered field; thus, adjuvant imatinib was deferred. Further tumour testing revealed an exon-11 KIT gene mutation. The patient is currently alive and functioning well 12 months later.

DISCUSSION
Although GISTs are the most common mesenchymal tumour of the GI tract, only 5% arise from the colorectum (1). Approximately 70% of GISTs are associated with clinical symptoms, namely GI bleeding, obstruction or abdominal pain (2). Eighty-five percent of GISTs harbour activating mutations in the KIT transmembrane receptor, usually in exon 11; this serves as the molecular target for tyrosine kinase inhibitors.
such as imatinib and sunitinib (3). Our case highlights typical GIST features arising from an unusual location. EUS was the key investigation to make the diagnosis preoperatively and provide the opportunity for neoadjuvant therapy. EUS can accurately delineate the origin of pelvic tumours around the rectum and enables safe tissue acquisition. Cell blocks from cytology specimens can be further characterized by immunohistochemistry. Therefore, although rare, a rectal GIST should be considered in a patient presenting with rectal outlet obstruction.

DISCLOSURES: The authors have no financial disclosures or conflicts of interest to declare.

REFERENCES